Paclitaxel Injection (Albumin-bound) for Neoadjuvant Treatment of Breast Cancer
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Neoadjuvant chemotherapy is a systemic cytotoxic drug therapy for non-metastatic tumors
before local therapy, Now it has become an important part of standard treatment for a stage
II, III, and the first clinical Ⅳ breast cancer .Both domestic and foreign authoritative
guidelines recommend the use of albumin-binding paclitaxel in the neoadjuvant treatment of
breast cancer .In addition, clinical studies at home and abroad have preliminarily confirmed
the application value and therapeutic benefit of albumin-binding paclitaxel in breast cancer
neoadjuvant therapy, and the toxic and side effects can be tolerated.